Attenuated Mengo virus: a new vector for live recombinant vaccines

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Mengo virus possesses advantageous characteristics for vaccine vector development, including a broad host range and cytoplasmic replication.
• Attenuated Mengo virus strains, modified in the 5' noncoding region, are available.
• Recombinant viral vectors are crucial for developing novel vaccines against infectious diseases.

Purpose of the Study:

• To engineer an attenuated Mengo virus recombinant, vLCMG4, expressing a cytotoxic T-lymphocyte (CTL) epitope from lymphocytic choriomeningitis virus (LCMV).
• To evaluate the efficacy of vLCMG4 as a vaccine candidate inducing cellular immunity against LCMV infection.

Main Methods:

• Construction of a recombinant Mengo virus (vLCMG4) encoding an LCMV nucleoprotein CTL epitope.
• Immunization of BALB/c mice with a single, low dose of vLCMG4.
• Assessment of protective immunity against lethal LCMV challenge.
• Analysis of LCMV-specific CD8+ cytotoxic T lymphocyte responses.

Main Results:

• The recombinant vLCMG4 successfully induced protective immunity against lethal LCMV infection after a single immunization in mice.
• A robust LCMV-specific CD8+ cytotoxic T lymphocyte response was elicited by vLCMG4 vaccination.
• The study demonstrated the induction of cellular immunity by the recombinant Mengo virus vaccine.

Conclusions:

• Recombinant Mengo virus vectors hold significant potential for vaccine development against infectious diseases.
• The induction of cellular immune responses, specifically CTL responses, is a viable strategy for protective immunity.
• vLCMG4 represents a promising vaccine candidate for conferring protection against LCMV through T-cell mediated immunity.